Estradiol Valerate
| 證據等級: L5 | 預測適應症: 10 個 |
目錄
- Estradiol Valerate
- Estradiol Valerate: From Estrogen Deficiency (Hormone Therapy) to Symptomatic Fragile X Syndrome Carrier State
Estradiol Valerate: From Estrogen Deficiency (Hormone Therapy) to Symptomatic Fragile X Syndrome Carrier State
One-Sentence Summary
Estradiol valerate is a synthetic estrogen ester generally used across its drug class for hormone replacement and menstrual cycle regulation, though no regulatory-approved indication text was recovered for this drug in the reviewed data sources. The TxGNN model’s top-ranked prediction is symptomatic form of fragile X syndrome in female carrier, but this candidate is currently supported by 0 clinical trials and 0 publications — it is a pure model-score prediction with no biological or clinical evidence behind it.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not available (no licenses/label text on file; estradiol valerate is generally used for estrogen replacement therapy as a drug class) |
| Predicted New Indication | Symptomatic form of fragile X syndrome in female carrier |
| TxGNN Prediction Score | 99.94% |
| Evidence Level | L5 |
| US Market Status | Not Marketed |
| Number of NDAs | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Detailed mechanism of action data is not currently available for estradiol valerate in this evidence pack. Based on general pharmacological knowledge, estradiol valerate is a synthetic ester of 17β-estradiol that is hydrolyzed to active estradiol after administration, acting on estrogen receptors (ERα/ERβ) throughout reproductive and neuroendocrine tissue.
For the top-ranked candidate indication, however, the evidence pack’s own rationale is explicit: no mechanistic link, clinical trial, or literature evidence connecting estradiol valerate to symptoms in female fragile X syndrome (FMR1 premutation) carriers could be found. The 99.94% score reflects the TxGNN knowledge-graph model’s relational prediction alone, not any established or hypothesized biological pathway. Fragile X-associated conditions in female carriers (including primary ovarian insufficiency, FXPOI) do involve secondary estrogen deficiency, which is the most plausible indirect rationale for the model’s association — but this remains a speculative inference, not a validated pharmacological hypothesis, and no source data corroborates it.
Because no similarity between an established original indication and this predicted indication can be assessed (original indication data itself is unavailable), the mechanistic plausibility of this specific candidate cannot be meaningfully evaluated at this time.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
Safety Considerations
Please refer to the package insert for safety information.
(Note: A regulatory-label safety review could not be completed — TFDA label warnings/contraindications and DDI data were not found in the sources queried (query IDs 1–2 in the evidence pack), which blocks progression to Stage 1 safety screening.)
Conclusion and Next Steps
Decision: Hold
Rationale: The top-ranked predicted indication (fragile X syndrome carrier symptoms) has no supporting clinical trials, literature, or established mechanistic rationale — it is a model-score-only (L5) prediction, and the drug itself has no on-file marketing authorization or label safety data in the reviewed sources, blocking any near-term safety assessment.
To proceed, the following is needed:
- Drug-level MOA data from DrugBank (currently a data gap, High severity)
- TFDA/FDA label warnings and contraindications (currently a data gap, Blocking severity — required before any Stage 1 safety evaluation)
- A targeted literature/mechanism search specifically on estrogen deficiency in FMR1-premutation carriers (e.g., FXPOI) to determine whether a genuine biological hypothesis can be constructed for this candidate
- Original indication and regulatory history for estradiol valerate, to enable a proper original-vs-predicted indication comparison
For context: other candidates in this same evidence pack carry substantially stronger evidence — notably ovarian dysfunction (rank 10, L2, Proceed with Guardrails, 50 clinical trials/20 publications) — and may warrant prioritization over this top-ranked but evidence-free candidate if the goal is near-term repurposing feasibility rather than strict TxGNN-rank order.
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.